文献速递白血病造血干细胞移植与细胞治疗

供者来源CD19 CAR-T治疗异基因移植后复发B-ALL

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.
PubMed 文献 · Leukemia · 2020-10-19

分析43例异基因移植后复发CD19阳性B-ALL受试者接受供者来源CD19 CAR-T细胞治疗的安全性和疗效。34例(79%;95%CI:66,92%)达到完全组织学缓解,细胞因子释放综合征发生38例(88%;78,98%),其中≥3级7例。1年无事件生存率和生存率为43%(25,62%)。

要点

  • 供者来源CD19 CAR-T治疗移植后复发B-ALL安全有效,完全缓解率79%。
  • 细胞因子释放综合征发生率高(88%),≥3级7例,需密切监测。
  • 1年无事件生存率和生存率为43%,与替代疗法相当但缺乏随机试验数据。

核心结论

  • 供者来源CD19 CAR-T细胞治疗异基因移植后复发CD19阳性B-ALL安全有效,但细胞因子释放综合征发生率高。

研究设计与样本

  • 分析43例异基因移植后复发B-ALL受试者接受供者来源CD19 CAR-T细胞治疗。

主要发现

  • 34例(79%;95%CI:66,92%)达到完全组织学缓解。
  • 细胞因子释放综合征发生38例(88%;78,98%),≥3级7例,2例死于多器官衰竭和细胞因子释放综合征。
  • 9例(21%;8,34%)发生≤2级免疫效应细胞相关神经毒性综合征,2例发生≤2级急性移植物抗宿主病。
  • 1年无事件生存率和生存率为43%(25,62%)。
  • 32例达到完全组织学缓解且未接受第二次移植者,1年累积复发率41%(25,62%),1年无事件生存率和生存率59%(37,81%)。

临床怎么用

  • 供者来源CD19 CAR-T可用于异基因移植后复发CD19阳性B-ALL,但需重点防治细胞因子释放综合征。

局限性

  • 缺乏随机试验数据,与替代疗法的比较需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells) in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after an allotransplant remain unclear. Forty-three subjects with B-ALL relapsing post allotransplant received CAR-T cells were analyzed. 34 (79%; 95% confidence interval [CI]: 66, 92%) achieved complete histological remission (CR). Cytokine release syndrome (CRS) occurred in 38 (88%; 78, 98%) and was ≥grade-3 in 7. Two subjects died from multiorgan failure and CRS. Nine subjects (21%; 8, 34%) developed ≤grade-2 immune effector cell-associated neurotoxicity syndrome (ICANS). Two subjects developed ≤grade-2 acute graft-versus-host disease (GvHD). 1-year event-free survival (EFS) and survival was 43% (25, 62%). In 32 subjects with a complete histological remission without a second transplant, 1-year cumulative incidence of relapse was 41% (25, 62%) and 1-year EFS and survival, 59% (37, 81%). Therapy of B-ALL subjects relapsing post transplant with donor-derived CAR-T cells is safe and effective but associated with a high rate of CRS. Outcomes seem comparable to those achieved with alternative therapies but data from a randomized trial are lacking.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhang C, Wang XQ, Zhang RL, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2020. PMID: 33077866. doi:10.1038/s41375-020-01056-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。